A new drug has cured 20% of patients with a chronic, cancer-causing disease — which was previously incurable. A viral ...
In an editorial published in the New England Journal of Medicine, University of Michigan Health hepatologist Anna S. Lok, M.D., hails newly announced results of the B-Well clinical trials as "a major ...
Two replicate phase 3 randomized controlled trials involving patients with chronic hepatitis B virus (HBV) infection demonstrate a functional cure after the discontinuation of conventional long-term ...
In HepG2.117 cells, ALG-001075 achieved HBV DNA EC50 0.64 nM, outperforming canocapavir (5.8 nM) and neracorvir (24 nM) with ...
After treatment with bepirovirsen, however, 19% of patients achieved the strictly defined “functional cure” criteria. For the ...
Hepatitis B virus (HBV) reactivation is commonly observed in individuals with chronic HBV infection undergoing antineoplastic drug therapy. Paclitaxel (PTX) treatment has been identified as a ...
Hepatitis B virus (HBV) reactivation is commonly observed in individuals with chronic HBV infection undergoing antineoplastic drug therapy. Paclitaxel (PTX) treatment has been identified as a ...
New research implies that a first-of-its-kind drug for hepatitis B could allow some patients to stop treatment without ...
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® ...
Two cross-sectional, one validation cohort, and meta-analyses were used to explore the relationship between HBV replication and liver inflammation. Spearman analysis, multiple linear regression, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results